The Xolair Pregnancy Registry: An Observational Study of the Use and Safety of Xolair (Omalizumab) During Pregnancy (EXPECT)

Trial Profile

The Xolair Pregnancy Registry: An Observational Study of the Use and Safety of Xolair (Omalizumab) During Pregnancy (EXPECT)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Jun 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Acronyms EXPECT
  • Sponsors Genentech
  • Most Recent Events

    • 26 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 05 Apr 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2017 as per ClinicalTrials.gov record.
    • 05 Apr 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top